• Akahata, W., Yang, Z.Y., Andersen, H., Sun, S., Holdaway, H.A., Kong, W.P., Lewis, M.G., Higgs, S., Rossmann, M.G., Rao, S., Nabel, G.J., 2010. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 16, 334–338.

  • Bahl, K., Senn, J.J., Yuzhakov, O., Bulychev, A., Brito, L.A., Hassett, K.J., Laska, M.E., Smith, M., Almarsson, O., Thompson, J., Ribeiro, A.M., Watson, M., Zaks, T., Ciaramella, G., 2017. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316–1327.

  • Basore, K., Kim, A.S., Nelson, C.A., Zhang, R., Smith, B.K., Uranga, C., Vang, L., Cheng, M., Gross, M.L., Smith, J., Diamond, M.S., Fremont, D.H., 2019. Cryo-EM structure of chikungunya virus in complex with the Mxra8 receptor. Cell 177, 1725–1737 e1716.

  • Borgherini, G., Poubeau, P., Jossaume, A., Gouix, A., Cotte, L., Michault, A., ArvinBerod, C., Paganin, F., 2008. Persistent arthralgia associated with chikungunya virus:a study of 88 adult patients on reunion island. Clin. Infect. Dis. 47, 469–475.

  • Brandler, S., Ruffié, C., Combredet, C., Brault, J.-B., Najburg, V., Prevost, M.-C., Habel, A., Tauber, E., Desprès, P., Tangy, F., 2013. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 31, 3718–3725.

  • Broeckel, R.M., Haese, N., Ando, T., Dmitriev, I., Kreklywich, C.N., Powers, J., Denton, M., Smith, P., Morrison, T.E., Heise, M., DeFilippis, V., Messaoudi, I., Curiel, D.T., Streblow, D.N., 2019. Vaccine-induced skewing of T cell responses protects against chikungunya virus disease. Front. Immunol. 10, 2563.

  • Burrack, K.S., Montgomery, S.A., Homann, D., Morrison, T.E., 2015. CD8+T cells control Ross River virus infection in musculoskeletal tissues of infected mice. J. Immunol. 194, 678–689.

  • Chang, L.-J., Dowd, K.A., Mendoza, F.H., Saunders, J.G., Sitar, S., Plummer, S.H., Yamshchikov, G., Sarwar, U.N., Hu, Z., Enama, M.E., Bailer, R.T., Koup, R.A., Schwartz, R.M., Akahata, W., Nabel, G.J., Mascola, J.R., Pierson, T.C., Graham, B.S., Ledgerwood, J.E., Team, tVS., 2014. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet. https:// doi.org/10.1016/S0140-6736(14)61185-52046-2052.

  • Chopra, A., Anuradha, V., Ghorpade, R., Saluja, M., 2011. Acute Chikungunya and persistent musculoskeletal pain following the 2006 Indian epidemic: a 2-year prospective rural community study. Epidemiol. Infect. 140, 842–850.

  • Chu, H., Das, S.C., Fuchs, J.F., Suresh, M., Weaver, S.C., Stinchcomb, D.T., Partidos, C.D., Osorio, J.E., 2013. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine 31, 3353–3360.

  • DeZure, A.D., Berkowitz, N.M., Graham, B.S., Ledgerwood, J.E., 2016. Whole-inactivated and virus-like particle vaccine strategies for chikungunya virus. JID (J. Infect. Dis.) 214, S497–S499.

  • ECDC, 2020. Communicable Disease Threats Report, 14- 20 June 2020, Week 25. Chikungunya and Dengue. Multistate (World). Monitoring global outbreaks. https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-14-20-june-2020-week-25.

  • Edelman, R., Tacket, C.O., Wasserman, S.S., Bodison, S.A., Perry, J.G., Mangiafico, J.A., 2000. Phase II safety and immunogenicity study of live Chikungunya virus vaccine TSI-GSD-218. Am. J. Trop. Med. Hyg. 62, 681–685.

  • Fox, J.M., Long, F., Edeling, M.A., Lin, H., van Duijl-Richter, M.K.S., Fong, R.H., Kahle, K.M., Smit, J.M., Jin, J., Simmons, G., Doranz, B.J., Crowe, J.E., Fremont, D.H., Rossmann, M.G., Diamond, M.S., 2015. Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress. Cell 163, 1095–1107.

  • Gwendolyn, K., Binder, D.E.G., 2001. Interferon-gamma-Mediated site-specific clearance of alphavirus from CNS neurons. Science 293, 303–306.

  • Hallengard, D., Kakoulidou, M., Lulla, A., Kummerer, B.M., Johansson, D.X., Mutso, M., Lulla, V., Fazakerley, J.K., Roques, P., Le Grand, R., Merits, A., Liljestrom, P., 2014a. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J. Virol. 88, 2858–2866.

  • Hallengard, D., Lum, F.M., Kummerer, B.M., Lulla, A., Lulla, V., Garcia-Arriaza, J., Fazakerley, J.K., Roques, P., Le Grand, R., Merits, A., Ng, L.F., Esteban, M., Liljestrom, P., 2014b. Prime-boost immunization strategies against Chikungunya virus. J. Virol. 88, 13333–13343.

  • Khan, M., Dhanwani, R., Rao, P.V., Parida, M., 2012. Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice. Virus Res. 167, 236–246.

  • Kim, D.Y., Atasheva, S., Foy, N.J., Wang, E., Frolova, E.I., Weaver, S., Frolov, I., 2011. Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype. J. Virol. 85, 4363–4376.

  • Kumar, M., Sudeep, A.B., Arankalle, V.A., 2012. Evaluation of recombinant E2 proteinbased and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 30, 6142–6149.

  • Li, L., Jose, J., Xiang, Y., Kuhn, R.J., Rossmann, M.G., 2010. Structural changes of envelope proteins during alphavirus fusion. Nature 468, 705–708.

  • Lum, F.-M., Teo, T.-H., Lee, W.W.L., Kam, Y.-W., Rénia, L., Ng, L.F.P., 2013. An essential role of antibodies in the control of chikungunya virus infection. J. Immunol. 190, 6295–6302.

  • Mallilankaraman, K., Shedlock, D.J., Bao, H., Kawalekar, O.U., Fagone, P., Ramanathan, A.A., Ferraro, B., Stabenow, J., Vijayachari, P., Sundaram, S.G., Muruganandam, N., Sarangan, G., Srikanth, P., Khan, A.S., Lewis, M.G., Kim, J.J., Sardesai, N.Y., Muthumani, K., Weiner, D.B., 2011. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Neglected Trop. Dis. 5, e928.

  • Masrinoul, P., Puiprom, O., Tanaka, A., Kuwahara, M., Chaichana, P., Ikuta, K., Ramasoota, P., Okabayashi, T., 2014. Monoclonal antibody targeting chikungunya virus envelope 1 protein inhibits virus release. Virology 464–465, 111–117.

  • Metza, S.W., Martinab, B.E., Pvd, Doelb, Geertsemaa, C., Osterhausb, A.D., Vlaka, J.M., Pijlman, G.P., 2013. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine.https://doi.org/10.1016/j.vaccine.2013.09.0456092-6096.

  • Muthumani, K., Block, P., Flingai, S., Muruganantham, N., Chaaithanya, I.K., Tingey, C., Wise, M., Reuschel, E.L., Chung, C., Muthumani, A., Sarangan, G., Srikanth, P., Khan, A.S., Vijayachari, P., Sardesai, N.Y., Kim, J.J., Ugen, K.E., Weiner, D.B., 2016. Rapid and long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against chikungunya virus. JID (J. Infect. Dis.) 214, 369–378.

  • PAHO, 2021. Cases of Chikungunya Virus Disease by Contury or Territory Cumulative Cases. https://www3.paho.org/data/index.php/en/mnu-topics/chikv-en/550-chik v-weekly-en.html.

  • Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Perez Marc, G., Moreira, E.D., Zerbini, C., Bailey, R., Swanson, K.A., Roychoudhury, S., Koury, K., Li, P., Kalina, W.V., Cooper, D., Frenck Jr., R.W., Hammitt, L.L., Tureci, O., Nell, H., Schaefer, A., Unal, S., Tresnan, D.B., Mather, S., Dormitzer, P.R., Sahin, U., Jansen, K.U., Gruber, W.C., Group, C.C.T., 2020. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615.

  • Pollard, C., Rejman, J., De Haes, W., Verrier, B., Van Gulck, E., Naessens, T., De Smedt, S., Bogaert, P., Grooten, J., Vanham, G., De Koker, S., 2013. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol. Ther. 21, 251–259.

  • Powers Acb, Ann M., Tesh, Robert B., Weaver, Scott C., 2000. Re-emergence of chikungunya and o’nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J. Gen. Virol. 81, 471–479.

  • Doel, P.V.D., Volz, A., Roose, J.M., Sewbalaksing, V.D., Pijlman, G.P., Iv, Middelkoop, Duiverman, V., Evd, Wetering, Sutter, G., Osterhaus, A.D.M.E., Martina, B.E.E., 2014. Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge. PLoS Neglected Trop. Dis. 8, e3101.

  • Ren, H., Wang, G., Wang, S., Chen, H., Chen, Z., Hu, H., Cheng, G., Zhou, P., 2016. Crossprotection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: a viable alternative to oseltamivir. mAbs 8, 1156–1166.

  • Richner, J.M., Himansu, S., Dowd, K.A., Butler, S.L., Salazar, V., Fox, J.M., Julander, J.G., Tang, W.W., Shresta, S., Pierson, T.C., Ciaramella, G., Diamond, M.S., 2017. Modified mRNA vaccines protect against Zika virus infection. Cell 168, 1114–1125 e1110.

  • Robinson, M.C., 1955. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952–53. I. Clinical features. Trans. R. Soc. Trop. Med. Hyg. 49, 28–32.

  • Sahin, U., Kariko, K., Tureci, O., 2014. mRNA-based therapeutics–developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780.

  • Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L.M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., Brachtendorf, S., Lorks, V., Sikorski, J., Hilker, R., Becker, D., Eller, A.K., Grutzner, J., Boesler, C., Rosenbaum, C., Kuhnle, M.C., Luxemburger, U., Kemmer-Bruck, A., Langer, D., Bexon, M., Bolte, S., Kariko, K., Palanche, T., Fischer, B., Schultz, A., Shi, P.Y., Fontes-Garfias, C., Perez, J.L., Swanson, K.A., Loschko, J., Scully, I.L., Cutler, M., Kalina, W., Kyratsous, C.A., Cooper, D., Dormitzer, P.R., Jansen, K.U., Tureci, O., 2020. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586, 594–599.

  • Smith, S.A., Silva, L.A., Fox, J.M., Flyak, A.I., Kose, N., Sapparapu, G., Khomandiak, S., Ashbrook, A.W., Kahle, K.M., Fong, R.H., Swayne, S., Doranz, B.J., McGee, C.E., Heise, M.T., Pal, P., Brien, J.D., Austin, S.K., Diamond, M.S., Dermody, T.S., Crowe Jr., J.E., 2015. Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against chikungunya virus. Cell Host Microbe 18, 86–95.

  • Song, H., Zhao, Z., Chai, Y., Jin, X., Li, C., Yuan, F., Liu, S., Gao, Z., Wang, H., Song, J., Vazquez, L., Zhang, Y., Tan, S., Morel, C.M., Yan, J., Shi, Y., Qi, J., Gao, F., Gao, G.F., 2019. Molecular basis of arthritogenic alphavirus receptor MXRA8 binding to chikungunya virus envelope protein. Cell 177, 1714–1724 e1712.

  • Suhrbier, A., 2019. Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat. Rev. Rheumatol. 15, 597–611.

  • Teo, T.H., Lum, F.M., Claser, C., Lulla, V., Lulla, A., Merits, A., Renia, L., Ng, L.F., 2013. A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice. J. Immunol. 190, 259–269.

  • Teo, T.-H., Chan, Y.-H., Lee, W.W.L., Lum, F.-M., Amrun, S.N., Her, Z., Rajarethinam, R., Merits, A., Rötzschke, O., Rénia, L., Ng, L.F.P., 2017. Fingolimod treatment abrogates chikungunya virus–induced arthralgia. Sci. Transl. Med. 9 (375), eaal1333.

  • Thiberville, S.D., Moyen, N., Dupuis-Maguiraga, L., Nougairede, A., Gould, E.A., Roques, P., de Lamballerie, X., 2013. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antivir. Res. 99, 345–370.

  • Tiwari, M., Parida, M., Santhosh, S.R., Khan, M., Dash, P.K., Rao, P.V.L., 2009. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 27, 2513–2522.

  • Tretyakova, I., Hearn, J., Wang, E., Weaver, S., Pushko, P., 2014. DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice. J. Infect. Dis. 209, 1882–1890.

  • Tsetsarkin, K.A., Vanlandingham, D.L., McGee, C.E., Higgs, S., 2007. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog. 3, e201.

  • Tsetsarkin, K.A., McGee, C.E., Volk, S.M., Vanlandingham, D.L., Weaver, S.C., Higgs, S., 2009. Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya virus to Aedes albopictus and Ae. aegypti mosquitoes. PLoS One 4, e6835.

  • Vogel, A.B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K.C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., Reece, S.T., Sahin, U., Tregoning, J.S., 2018. Selfamplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol. Ther. 26, 446–455.

  • Volk, S.M., Chen, R., Tsetsarkin, K.A., Adams, A.P., Garcia, T.I., Sall, A.A., Nasar, F., Schuh, A.J., Holmes, E.C., Higgs, S., Maharaj, P.D., Brault, A.C., Weaver, S.C., 2010. Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates. J. Virol. 84, 6497–6504.

  • Voss, J.E., Vaney, M.C., Duquerroy, S., Vonrhein, C., Girard-Blanc, C., Crublet, E., Thompson, A., Bricogne, G., Rey, F.A., 2010. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature 468, 709–712.

  • Weaver, S.C., Weber, C., Berberich, E., von Rhein, C., Henß, L., Hildt, E., Schnierle, B.S., 2017. Identification of functional determinants in the chikungunya virus E2 protein. PLoS Neglected Trop. Dis. 11, e0005318.

  • Zhang, M., Sun, J., Li, M., Jin, X., 2020. Modified mRNA-LNP vaccines confer protection against experimental DENV-2 infection in mice. Molecular Therapy - Methods & Clinical Development. 18, 702–712.